ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 716

The Active Metabolite Of Spleen Tyrosine Kinase Inhibitor Fostamatinib Abrogates The T Cell Priming Capacity Of Dendritic Cells

Andrew Platt1, Ross McQueenie1, Robert Benson2, John Butcher1, Martin Braddock3, James M. Brewer4, Iain B. McInnes1 and Paul Garside1, 1Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, 2Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, 3AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, 4Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: SYK, T cells and dendritic cells

  • Tweet
  • Email
  • Print
Session Information

Session Title: T-cell Biology and Targets in Autoimmune Disease: Signaling Pathways in T-cell Differentiation

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Spleen tyrosine kinase (SYK) is a core signaling protein that drives inflammatory responses and is fundamental to the propagation of signals via numerous immune-receptors including the B cell receptor (BCR) and Fc receptors (FcRs). The small molecule SYK inhibitor, fostamatinib, has shown evidence of ameliorating inflammation in rheumatoid arthritis (RA) patients. We sought to understand how the active metabolite of fostamatinib, R406, affects the inflammatory response at the cellular level. It has been shown that R406 reduces the response of dendritic cells (DCs) to immune complexes (ICs) and we have previously demonstrated that the area and duration of interaction between T cells and DCs are key determinants in the outcome of an immune response.

Methods:

Fluorescence microscopy was combined with CD4+ T cells from T cell receptor transgenic OT-II mice to track antigen-specific interactions between DCs and T cells in vitro.

Results:

We have found that R406 reduces the DC-T cell contact area and the number of interactions lasting more than 5 minutes during the initial phase of cellular cross-talk between IC-activated DCs and antigen-specific CD4+ T cells. This led to diminished proliferation with 19.2±0.5% of OT-II CD4+ T cells undergoing proliferation (and only a maximum of two rounds) after R406 treatment compared with 79.6±2.0% in vehicle controls. This reduced proliferative capacity of CD4+ T cells was accompanied by reduced expression of the co-stimulatory molecules, ICOS and PD-1, and total blockade of the production of inflammatory cytokines such as IFNg and IL-17.

Conclusion:

Our findings indicate a potential mechanism via which this compound may be effective in inhibiting FcR-driven T cell responses and ameliorating chronic articular inflammation.


Disclosure:

A. Platt,
None;

R. McQueenie,
None;

R. Benson,
None;

J. Butcher,
None;

M. Braddock,

AstraZeneca,

1,

AstraZeneca,

3;

J. M. Brewer,
None;

I. B. McInnes,
None;

P. Garside,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-active-metabolite-of-spleen-tyrosine-kinase-inhibitor-fostamatinib-abrogates-the-t-cell-priming-capacity-of-dendritic-cells/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences